Domov › Rakovina prsníka › Connecticut › Bridgeport
Klinické štúdie Rakovina prsníka v meste Bridgeport, CT
21 štúdií pre Rakovina prsníka hľadá účastníkov v zariadeniach v meste Bridgeport a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.
Oficiálny text štúdie (anglicky)
Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Prebieha náborObservačná štúdiaVítaní zdravých dobrovoľníkov
- Stony Brook University Medical Center, Stony Brook · 18 míľ odtiaľ
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Prebieha náborFáza 3
- Stony Brook University-Cancer Center ( Site 0034), Stony Brook · 18 míľ odtiaľ
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Prebieha náborFáza 3
- Research Site, Stony Brook · 18 míľ odtiaľ
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Prebieha náborFáza 3
- Smilow Cancer Hospital Care Center - Trumbull, Trumbull · 4 míľ odtiaľ
- Smilow Cancer Hospital Care Center - Fairfield, Fairfield · 5 míľ odtiaľ
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Prebieha nábor
- Stony Brook Cancer Center, Stony Brook · 18 míľ odtiaľ
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Prebieha náborFáza 1/2
- Stony Brook University Hospital, Stony Brook · 18 míľ odtiaľ
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Prebieha náborFáza 3
- Stony Brook University Medical Center, Stony Brook · 18 míľ odtiaľ
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Prebieha náborFáza 3
- Stony Brook University Cancer Center, Stony Brook · 18 míľ odtiaľ
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Prebieha náborFáza 3
- New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C. (Port Jefferson Station2), Port Jefferson Station · 19 míľ odtiaľ
- New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C.(Port Jefferson Station1), Port Jefferson Station · 19 míľ odtiaľ
- New York Cancers & Blood Specialists, Port Jefferson Station · 19 míľ odtiaľ
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Prebieha náborFáza 3
- Hartford HealthCare - Saint Vincent's Medical Center, Bridgeport
- Smilow Cancer Hospital Care Center-Trumbull, Trumbull · 4 míľ odtiaľ
- Smilow Cancer Hospital Care Center-Fairfield, Fairfield · 5 míľ odtiaľ
- a 1 ďalších
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
Prebieha náborFáza 2
- Stony Brook Cancer Center, Stony Brook · 18 míľ odtiaľ
ATEMPT 2.0: Adjuvant T-DM1 vs TH
Prebieha náborFáza 2
- Smilow Cancer Hospital Care center at Trumbull, Trumbull · 4 míľ odtiaľ
- Smilow Cancer Hospital Care center at Fairfield, Fairfield · 5 míľ odtiaľ
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
Prebieha náborFáza 1
- New York Cancer and Blood Specialists, Port Jefferson Station · 19 míľ odtiaľ
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Prebieha náborFáza 3
- Stony Brook University Cancer Center, Stony Brook · 18 míľ odtiaľ
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Prebieha náborFáza 3
- Smilow Cancer Hospital - Fairfield, Fairfield · 5 míľ odtiaľ
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Prebieha náborFáza 3
- Smilow Cancer Hospital Care Center-Trumbull, Trumbull · 4 míľ odtiaľ
- Smilow Cancer Hospital Care Center-Fairfield, Fairfield · 5 míľ odtiaľ
- Stony Brook University Medical Center, Stony Brook · 18 míľ odtiaľ
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Prebieha náborObservačná štúdia
- Stony Brook Medicine, Stony Brook · 18 míľ odtiaľ
Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer
Prebieha náborSkorá fáza 1
- Stony Brook Breast Center, Stony Brook · 18 míľ odtiaľ
Definitive Radiation Therapy for Inoperable Breast Cancer
Prebieha nábor
- Stony Brook University Cancer Center, Stony Brook · 18 míľ odtiaľ
Definitive Radiation for High-Risk Spine Metastases
Prebieha náborFáza 2
- Stony Brook University Hospital, Stony Brook · 18 míľ odtiaľ
CtDNA Based MRD Testing for NAC Monitoring in TNBC
Prebieha náborObservačná štúdia
- Stony Brook University Cancer Center, Stony Brook · 18 míľ odtiaľ
Štúdie Rakovina prsníka v iných mestách
- New York City, NY136 štúdií
- Houston, TX126 štúdií
- Boston, MA112 štúdií
- Nashville, TN81 štúdií
- Los Angeles, CA73 štúdií
- Edison, NJ68 štúdií
- St. Louis, MO64 štúdií
- Queens, NY64 štúdií
- Durham, NC64 štúdií
- Chicago, IL59 štúdií
- Philadelphia, PA56 štúdií
- Dallas, TX55 štúdií
Iné štúdie v Bridgeport
- Nemalobunkový karcinóm pľúc14 štúdií
- Rakovina pľúc13 štúdií
- Akútna myeloidná leukémia12 štúdií
- Kardiovaskulárne ochorenia9 štúdií
- Rakovina (všetky typy)8 štúdií
- Skvamóznocelulárny karcinóm hlavy a krku8 štúdií
- Metastatická rakovina7 štúdií
- Srdcové zlyhanie7 štúdií
- Aneurizma mozgu6 štúdií
- Mnohonásobný myelóm6 štúdií
- Rakovina prostaty6 štúdií
- Rakovina vaječníkov5 štúdií
Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.